KR20240144291A - T형 칼슘 채널 조절제를 사용하는 치료 방법 - Google Patents

T형 칼슘 채널 조절제를 사용하는 치료 방법 Download PDF

Info

Publication number
KR20240144291A
KR20240144291A KR1020247029049A KR20247029049A KR20240144291A KR 20240144291 A KR20240144291 A KR 20240144291A KR 1020247029049 A KR1020247029049 A KR 1020247029049A KR 20247029049 A KR20247029049 A KR 20247029049A KR 20240144291 A KR20240144291 A KR 20240144291A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
formula
compound
propranolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029049A
Other languages
English (en)
Korean (ko)
Inventor
버나드 라비나
Original Assignee
프락시스 프리시젼 메디신즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프락시스 프리시젼 메디신즈, 인크. filed Critical 프락시스 프리시젼 메디신즈, 인크.
Publication of KR20240144291A publication Critical patent/KR20240144291A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247029049A 2022-02-03 2023-02-03 T형 칼슘 채널 조절제를 사용하는 치료 방법 Pending KR20240144291A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306340P 2022-02-03 2022-02-03
US63/306,340 2022-02-03
PCT/US2023/061973 WO2023150703A2 (en) 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
KR20240144291A true KR20240144291A (ko) 2024-10-02

Family

ID=87552982

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029049A Pending KR20240144291A (ko) 2022-02-03 2023-02-03 T형 칼슘 채널 조절제를 사용하는 치료 방법

Country Status (10)

Country Link
US (1) US20250170114A1 (https=)
EP (1) EP4472633A4 (https=)
JP (1) JP2025505578A (https=)
KR (1) KR20240144291A (https=)
CN (1) CN118785905A (https=)
AU (1) AU2023216271A1 (https=)
CA (1) CA3243616A1 (https=)
IL (1) IL314576A (https=)
MX (1) MX2024009559A (https=)
WO (1) WO2023150703A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500340A (ja) * 2005-06-29 2009-01-08 メルク エンド カムパニー インコーポレーテッド 4−フルオロ−ピペリジンt型カルシウムチャネルアンタゴニスト
EP3340988B1 (en) * 2015-11-12 2025-04-09 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
US11744825B2 (en) * 2018-08-28 2023-09-05 Afasci, Inc. Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
IL297642A (en) * 2020-04-29 2022-12-01 Praxis Prec Medicines Inc Methods for using t-type calcium channel modulators
US20240025852A1 (en) * 2020-11-09 2024-01-25 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Also Published As

Publication number Publication date
EP4472633A2 (en) 2024-12-11
US20250170114A1 (en) 2025-05-29
CA3243616A1 (en) 2023-08-10
EP4472633A4 (en) 2026-01-14
WO2023150703A2 (en) 2023-08-10
AU2023216271A1 (en) 2024-08-15
JP2025505578A (ja) 2025-02-28
CN118785905A (zh) 2024-10-15
MX2024009559A (es) 2024-09-23
WO2023150703A3 (en) 2023-09-14
IL314576A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
US12077502B2 (en) Formulations of T-type calcium channel modulators and methods of use thereof
US10265304B2 (en) Nootropic compositions for improving memory performance
AU2021263804A1 (en) Methods of use of T-type calcium channel modulators
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
KR20240144291A (ko) T형 칼슘 채널 조절제를 사용하는 치료 방법
EP4673132A1 (en) Methods of treating essential tremor
WO2026085384A1 (en) Methods of treating essential tremor
JP2026507195A (ja) 高用量単回投与製剤及びその使用の方法
WO2025188619A1 (en) Methods of treating parkinson's disease with t-type calcium channel modulators
HK40012437A (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000